Update Your ProfileAcademic Title:
Professor
Primary Appointment:
Radiation Oncology
Administrative Title:
Senior Vice Chair for Research
Phone (Primary):
410-369-5233
Fax:
410-347-0870
Education and Training
Degrees
- MD PhD; Oregon Health and Sciences University - School of Medicine (2003)
Residencies
- Radiation Oncology; Stanford University School of Medicine (2008)
Board Certifications
- American Board of Radiology (Radiation Oncology) (2009)
Biosketch
Dr. Phuoc T. Tran is Professor and Senior Vice Chair for Research of Radiation Oncology at the University of Maryland School of Medicine.
Dr. Tran treats patients with cancers of the genitourinary system and uses stereotactic radiation techniques (such as SRS and SBRT/SABR) for the treatment of patients with oligometastatic disease. His research focuses on the improvement of clinical radiotherapy for the treatment of primarily prostate cancer, but also adrenal, bladder, urethral, testicular and penile cancer as well as patients with oligometastatic disease.
Dr. Tran completed his medical and graduate training at the Oregon Health & Sciences University in Portland. He conducted a residency in radiation oncology at the Stanford University Medical Center and spent a decade on the faculty of Johns Hopkins reaching the level of tenured Professor before joining the University of Maryland.
Dr. Tran has published more than 225 scholarly works, has received numerous awards for his research, and is a primary investigator on a number of clinical trials. He is a member, holds/has held leadership positions in the American Association for Cancer Research (AACR), Radiological Society of North America (RSNA), NRG Oncology and the American Society for Radiology Oncology (ASTRO), and is board certified in radiation oncology by the American Board of Radiology. He is also a senior editor for Cancer Research.
Please visit:
https://www.tranlaboratory.com/
Research/Clinical Keywords
Radiosensitizers; Genetically engineered mouse models of disease; Epithelial Plasticity (Epithelial-Mesenchymal Transition and Mesenchymal-Epithelial Transition); oligometastasis
Highlighted Publications
Phuoc T. Tran*, Pavan K. Bendapudi*, H. Jill Lin*, Peter Choi, Shan Koh, Joy Chen, George Horng, Nicholas P. Hughes, Lawrence H. Schwartz, Vincent A. Miller, Toshiyuki Kawashima, Toshio Kitamura, David Paik+ and Dean W. Felsher+. Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation. Sci Transl Med 3 (2011) 103ra99**. PMID: 21974937; PMCID: PMC3966995.* - these authors contributed equally; and + - corresponding authors
Reem Malek*, Hailun Wang*, Kekoa Taparra, Phuoc T. Tran. Therapeutic targeting of epithelial plasticity programs – Focus on the epithelial-mesenchymal transition. Cells Tissues Organs 203 (2017) 114-127. PMID: 28214899. PMCID: PMC5375029.* - these authors contributed equally.
Jeffrey J. Tosoian, Michael A. Gorin, Ashley E. Ross, Kenneth J. Pienta, Phuoc T. Tran, Edward M. Schaeffer. Oligometastatic Prostate Cancer: Definitions, Clinical Outcomes, and Treatment Considerations. Nat Rev Urol 14 (2017) 15-25. PMID: 27725639.
Kekoa Taparra*, Hailun Wang*, Reem Malek*, Audrey Lafargue, Mustafa A. Barbhuiya, Xing Wang, Brian W. Simons, Matthew Ballew, Katriana Nugent, Jennifer Groves, Russell D. Williams, Takumi Shiraishi, James Verdone, Gokben Yildirir, Roger Henry, Bin Zhang, John Wong, Ken K. Wang, Barry D. Nelkin, Kenneth J. Pienta, Dean Felsher, Natasha E. Zachara+, Phuoc T. Tran+. O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. J Clin Invest 128 (2018) 4924-4937**. PMID 30130254. PMCID: PMC6205381.* - these authors contributed equally; and + - corresponding authors. ** - Highlighted in Cancer Res – Breaking Advances
Ryan Phillips, William Yue Shi, Matthew Deek, Noura Radwan, Su Jin Lim, Emmanuel S. Antonarakis, Steven P. Rowe, Ashley Ross, Michael A. Gorin, Curtiland Deville, Stephen C Greco, Hailun Wang, Samuel R. Denmeade, Channing J. Paller, Shirl Dipasquale, Theodore L. DeWeese, Daniel Y. Song, Hao Wang, Michael A. Carducci, Kenneth J. Pienta, Martin G. Pomper, Adam P. Dicker, Mario A. Eisenberger, Ash A. Alizadeh, Maximilian Diehn, Phuoc T. Tran. Outcomes of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr – The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 6(2020) 650-659**. PMID 32215577. PMCID: PMC7225913. ** - Editorial in JAMA Oncol, Ranked by Altmetric in top 10% of JAMA Oncol papers & Highlighted in Cancer Discovery & Nat Rev Urol
Felix Y Feng+, Huei-Chung (Rebecca) Huang, Daniel E. Spratt, Howard M Sandler, Jeffrey P Simko, Elai Davicioni, Paul L Nguyen, Alan Pollack, Jason A Efstathiou, Adam P Dicker, Rajdeep Das, James Dignam, Darby JS Thompson, Shuang Zhao, Tamara Todorovic, Jennifer Margrave, Yang Liu, Bashar Dabbas, Christopher J. Sweeney, Gerhardt Attard, Jean-Paul Bahary, Himanshu R Lukka, William A Hall, Thomas M Pisansky, Amit B Shah, Stephanie L Pugh, William U Shipley, Phuoc T Tran+. Validation of a 22-Gene Genomic Classifier in Patients with Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol 7 (2021) 544-552**. PMID 33570548. PMCID: PMC7879385. + - corresponding authors** - Editorial in JAMA Oncol and Ranked by Altmetric in top 10% of JAMA Oncol papers (https://jamanetwork.altmetric.com/details/99977450#score).
Matthew P. Deek, Kim Van der Eecken, Ryan Phillips, Neil R. Parikh, Pedro Isaacsson Velho, Tamara Lotan, Amar U. Kishan, Tobias Maurer, Movember GAP6 Consortium, Paul C. Boutros, Christopher Hovens, Matthew Abramowtiz, Alan Pollack, Neil Desai, Bradley Stish, Felix Y. Feng, Mario Eisenberger, Michael Carducci, Kenneth J. Pienta, Channing J. Paller, Emmanuel S. Antonarakis, Alejandro Berlin, Piet Ost, Phuoc T. Tran. The mutational landscape of metastatic castration-sensitive prostate cancer – the spectrum theory revisited. Eur Urol 80 (2021) 632-640. PMID 33419682.
Matthew P. Deek*, Kim Van der Eecken*, Philip Sutera, Rebecca A. Deek, Dries Reynders, Valérie Fonteyne, Adrianna A. Mendes, Karel Decaestecker, Ana Ponce Kiess, Nicolaas Lumen, Ryan Phillips, Aurélie De Bruycker, Mark Mishra, Zaker Rana, Jason Molitoris, Bieke Lambert, Louke Delrue, Hailun Wang, Kathryn Lowe, Sofie Verbeke, Jo Van Drope, Renée Bultijnck, Geert Villeirs, Kathia De Man, Filip Ameye, Daniel Y. Song, Theodore DeWeese, Channing J. Paller, Felix Y. Feng, Alexander Wyatt, Kenneth J. Pienta, Maximillian Diehn, Søren M. Bentzen, Steven Joniau, Friedl Vanhaverbeke, Gert De Meerleer, Emmanuel S. Antonarakis, Tamara L. Lotan, Alejandro Berlin, Shankar Siva, Piet Ost+, Phuoc T. Tran+. Long Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol 40 (2022) 3377-3382**. PMID: 36001857.
Philip Sutera, Yang Song, Kim Van der Eecken, Amol C. Shetty, Keara English, Theresa Hodges, Jinhee Chang, Valérie Fonteyne, Zaker Rana, Lei Ren, Adrianna A. Mendes, Nicolaas Lumen, Louke Delrue, Sofie Verbeke, Kathia De Man, Daniel Y. Song, Kenneth Pienta, Felix Y. Feng, Steven Joniau, Tamara Lotan, Barton Lane, Ana Kiess, Steven Rowe, Martin Pomper, Theodore DeWeese, Matthew Deek, Christopher Sweeney, Piet Ost+, Phuoc T. Tran+. Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer. Eur Urol 84 (2023) 531-535. PMID: 37173210. PMCID: PMC10636237.
Research Interests
Dr. Tran’s research focuses on the improvement of clinical radiotherapy for the treatment of primarily prostate, as well as adrenal, bladder, penile, testicular and urethral cancer. To learn how tumors arise, how they spread and why some cancers are resistant to treatment, he studies tumor cell epithelial plasticity - transitions of epithelial and mesenchymal cellular states.
Dr. Tran and his laboratory focus their studies on tumor cell epithelial plasticity - the transitions between epithelial and mesenchymal cellular states and the implications of these transitions for tumorigenesis, cancer treatment resistance and radiation-induced fibrosis. Their research utilizes a variety of inducible transgenic mouse models, non-invasive rodent imaging as well as more traditional molecular, biochemical and cell biologic approaches. One of these transitions, known as epithelial-mesenchymal transition (EMT), is a conserved developmental program that when inappropriately activated in post-natal life has been associated with organ fibrosis, tumorigenesis and metastasis.
A major focus of the laboratory is the use of inducible mouse models to simulate molecularly targeted therapies for malignancies and radiation induced late effects.
Another focus of the laboratory is the study of novel targeted agents as tumor selective radiosensitizers to increase the therapeutic ratio of clinical radiotherapy.
The Tran lab is committed to translating discoveries from the laboratory bench into novel cancer prevention, diagnostic and treatment approaches that can be tested in the clinic.
Please visit:
Clinical Specialty Details
Adrenal Cancer, Bladder Cancer, Image-Guided Radiation Therapy, Intensity-Modulated Radiation Therapy (IMRT), Metastatic Bone Disease, Metastatic Disease, Oligometastatic Disease, Penile Cancer, Prostate Cancer, Radiation Oncology, Stereotactic Body Radiation Therapy, Testicular Cancer, Urethral Cancer
Awards and Affiliations
Honors
- Fellow, Henry S. Kaplan Research, 2007
- Alpha Omega Alpha Honor Medical Society Alumni Award, Oregon Health & Sciences University Chapter, 2013
- Fellow, Parker B. Francis, 2008 - 2011
- Fellow, Radiological Society of North America Research, 2008
- John Muir College Caledonian Honor Society, University of California, 1995
- 1R01CA166348-01A1, National Cancer Institute , 2013 - 2018
- Sidney Kimmel Translational Scholar Award, 2013 - 2015
- Patrick C. Walsh Prostate Cancer Research Fund Award, 2013 - 2014
- Early Career Achievement Award, Oregon Health & Sciences University School of Medicine Alumni Association , 2013
- Research Scholar, American Cancer Society , 2012 - 2016
- Uniting Against Lung Cancer Award, 2012 - 2014
- Included among Top Doctors, Baltimore Magazine, 2012
- Educator of The Year, Association of Residents in Radiation Oncology (ARRO) , 2012
- Prostate Cancer Physician Research Training Award, DoD , 2011 - 2016
- The Phyllis and Brian L. Harvey Scholar - Patrick C. Walsh Prostate Cancer Research Fund Award, 2011 - 2013
- Junior Faculty Career Research Training Award, ASTRO, 2009 - 2011
- Malcolm A. Bagshaw Award, 2007
- Methods in Clinical Cancer Research Workshop Scholarship, ASCO/AACR , 2007
- Research Resident, Radiological Society of North America , 2006
- Roentgen Resident Research Award, Radiological Society of North America , 2006
- Deans Medical Student Research Award, OHSU, 2003
- Molecular Hematology Research Training Fellow, OHSU, 1998 - 2001
- Laurel Merit MD/PhD Scholar, OHSU, 1996 - 2003
- Graduated magna cum laude, University of California, 1996
- Regents Scholar, University of California, 1995 - 1996
- Johns Hopkins Catalyst Award, 2015
- ASCO Leadership Development Program, 2015
- Movember Foundation-PCF Challenge Award, 2015
- Johns Hopkins Discovery Award, 2016 - 2017
- 1R21CA223403-01-01, National Cancer Institute, 2018
- 1U01CA212007-01A1, National Cancer Institute, 2018
- 1U01CA231776-01, National Cancer Institute, 2018
- 1U01CA231776-S1, National Cancer Institute, 2021
- 1U54CA273956-01 - Radiation Oncology-Biology Integration Network (ROBIN) Oligometastasis (OligoMET) Center, National Cancer Institute, 2022
- ASTRO Mentorship Award, 2023
- NCI 1R01CA271540-01A1, 2023
Memberships
- Alpha Omega Alpha Honor Medical Society , 2013
- American Association for Cancer Research , 2007
- American College of Radiation Oncology , 2005
- American College of Radiology, 2004
- American Society for Radiation Oncology, 2004
- American Society of Clinical Oncology , 2007
- American Thoracic Society, 2008 - 2012
- Radiation Research Society , 2011
- Radiological Society of North America , 2004
- The EMT International Association , 2011
Grants and Contracts
1U01CA231776-01 Hann/Marchionni/Tran (PI) 09/03/18-08/31/24 NCE
NCI
Bioinformatic-Chemical Approach to Credential Molecular Targets to Combat Rapid Chemo-Radiation Resistance in SCLC
Role: MPI
20CHAL03 Pienta/Tran (PI) 1/1/21-12/31/24 NCE
Movember-Distingished Gentlemen’s Ride-PCF Challenge
“Radiolabeled systemic therapy with SABR for castration sensitive prostate cancer oligometastatic disease”
Role: MPI
3U01CA231776-03S1 Hann/Marchionni/Tran (PI) 04/01/21-08/31/24 NCE
NCI
Tumor-barcoding coupled with high-throughput sequencing of a novel chemoradiation resistant SCLC mouse model
Role: MPI
W81XWH-21-1-0296 Tran (PI) 5/1/21-4/30/24
Dept of Defense CDMRP Prostate Cancer Research Program
Novel biomarkers to direct stereotactic ablative radiotherapy in castration-sensitive oligometastatic prostate cancer
Role: PI
1U54CA273956-01 Sawant/Simone/Tran (PI) 8/01/22-07/30/27
NCI
Radiation Oncology-Biology Integration Network on Oligometastasis (ROBIN OligoMET) Center
Role: Contact PI
1R01CA271540-01A1 McFarland/Tran (PI) 1/1/23-12/31/27
NCI
Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLC
Role: PI